> Potentially, antibodies, as a functional category of therapeutic, may very well be on their way out. I’m a bit confused as to what you reference here but I’m

> Potentially, antibodies, as a functional category of therapeutic, may very well be on their way out. I’m a bit confused as to what you reference here but I’m assuming monoclonal (mAbs). I apologize I did not read your prior post. The market estimates are quite optimistic in this category such as: > Antibodies are the dominant class of protein therapeutics with over 160 antibody therapeutics currently licensed globally and a market value expected to reach $445 billion in the next five years https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10983868/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10983868/ Are you aware that BARDA is investing $5 billion into therapeutics like monoclonals/polyclonal for COVID-19 countermeasures? Their major focus is on many of the problems you stated and they want to drive costs down: https://youtu.be/t9lrPDxLsfw?si=T87jPBinbuTtDad_ https://youtu.be/t9lrPDxLsfw?si=T87jPBinbuTtDad_ Monoclonal antibodies seem like they finally are reaching the golden age based on their use earlier this pandemic, novel findings for rejuvenating our immune system, and even targeting other notable chronic diseases. https://medicalcountermeasures.gov/nextgen/ https://medicalcountermeasures.gov/nextgen/ https://www.nih.gov/news-events/nih-research-matters/rejuvenating-immune-system-depleting-certain-stem-cells https://www.nih.gov/news-events/nih-research-matters/rejuven... https://www.nih.gov/news-events/news-releases/nih-scientists-find-weak-points-epstein-barr-virus https://www.nih.gov/news-events/news-releases/nih-scientists... The primer in the next generation is wonderful. I’d love to see nanobodies created for SCV2 as soon as possible. The interesting part is that these platforms that BARDA are helping get online will help us pivot to any threats and use these next generation vehicles to respond. Keep an eye on vaccines too as they are going through a moment of next generation vehicles as well. I.e. multiple antigens, mucosal deliver, etc.